Purchase this article with an account.
Muneo Yamaguchi, Shintaro Nakao, Yoshihiro Kaizu, Yoshiyuki Kobayashi, Takahito Nakama, Shigeo Yoshida, Yuji Oshima, Tatsuro Ishibashi, Koh-hei Sonoda, Yoshio Kaneko, Tomoyuki Isobe; Therapeutic potential of topical ROCK inhibitor Ripasudil (K-115) in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1109.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Anti-VEGF therapy is widely used for age related macular degeneration in clinic. However, frequent intravitreal injections are needed for maximum effect. In this study, we investigated the therapeutic potential of a topical Rho-associated protein kinase (ROCK) inhibitor, ripasudil (K-115), in pathological choroidal neovascularization (CNV).
C57BL/6J mice underwent retinal laser photocoagulation to induce CNV. Experiment 1. Ripasudil (3 or 30 µmol/L) as well as aflibercept were treated intravitreally every 3 days after laser injury. Experiment 2. A physiological saline solution, a 0.4% ripasudil ophthalmic solution, or a 0.8% ripasudil ophthalmic solution was applied topically to both eyes of the animals 3 times daily for 7 days. The volume of CNV was quantified with choroidal flat mounts stained by lectin.
1. Intravitreal ripasudil treatment could reduce the volumes of CNV significantly at the similar level of aflibercept treatment (49% reduction from baseline at 3 µmol/L ripasudil; p<0.01 vs control, 56% reduction at 30 µmol/L ripasudil; p<0.01 vs control). 2. The volumes of CNV at day 7 after laser injury was significantly reduced in a 0.8% ripasudil ophthalmic solution groups (32% reduction from baseline at 0.4% ripasudil; p=0.06 vs saline, 41% reduction at 0.8% K-115; p=0.03 vs saline).
Topical as well as intravitreal ripasudil treatment has the potential to become a novel therapeutic strategy in the treatment of choroidal neovascularization.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only